A practical reference on heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-23 and is reviewed periodically as new material appears.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
=== Data breach === According to an October 2020 report, for months, the company stored hundreds of massive spreadsheets containing sensitive patient data in an Amazon Web Services storage bucket without a password. TechCrunch was the first news source to report the data breach.
{\displaystyle \mu ={\frac {1}{j+1}}{\Bigl \langle }(l,s),j,m_{j}{=}j\,{\Bigr |}\left({\frac {1}{2}}{\vec {l}}{g^{(l)}}_{p}+{\frac {1}{2}}{\vec {s}}({g^{(s)}}_{p}+{g^{(s)}}_{n})\right)\cdot {\vec {\jmath }}\,{\Bigl |}\,(l,s),j,m_{j}{=}j{\Bigr \rangle }}
== Research == In addition to muscle spasticity, tizanidine was under development for the treatment of fibromyalgia and migraine, but development for these indications was discontinued. Several other formulations have also been developed for various indications, including spastic paralysis, musculoskeletal pain, and back pain, but likewise have not been marketed. An intranasal formulation was in phase 3 clinical trials for back pain as of 2017.
Sources: en.wikipedia.org
Olaf College Elio Di Rupo (born 1951), Prime Minister of Belgium Israel Shahak (1933–2001), Israeli chemist and civil-rights activist Margaret Thatcher (1925–2013), Prime Minister of the United Kingdom (1979–1990), research chemist at BX Plastics
His drawing repertoire culminated in an exhibition titled IndigNation, which opened on October 23, 2018, at the Maccarone Gallery in Los Angeles and featured 108 pen-and-ink drawings from Carrey's Twitter feed from 2016 to 2018. In February 2021, Carrey announced he would discontinue political cartoons. In a 2004 interview with 60 Minutes, Carrey reportedly said, "I'm a Buddhist, I'm a Muslim, I'm a Christian." In June 2017, Carrey delivered a speech at a Homeboy Industries event, where he said, “I want to speak to the fact that I believe that this room is filled with God, and that you are heroes to me and I admire you.” He also said, "You've made the decision to walk through the gate of forgiveness, of grace, just as Christ did on the cross."
== General characteristics == Stichodactyla helianthus is a tropical anemone commonly known as the “Sun Anemone” and part of the order Actiniaria, which comprises the sea anemones of the class Anthozoa. Described posthumously by John Ellis in 1786, these organisms, like all Anthozoa, are documented by the absence of an operculum–a calcareous shell in a circular form. Anthozoans also possess circular mitochondrial DNA and siphonoglyphs (ciliated grooves) in the pharyngeal wall. Another predominant trait resides in the presence of the coelenteron around the centralized body cavity, which is divided by distinct septa. In terms of reproductive distinction, this species lacks a medusa stage and exhibits the polyp stage exclusively.
Sources: en.wikipedia.org
Steve Biko (They Fought for Freedom). Maskew Miller Longman. ISBN 978-0-636-01660-6. Tutu, Desmond (1996). The Rainbow People of God. Image. ISBN 978-0-385-48374-2. Van Wyk, Chris (2007). We Write What We Like: Celebrating Steve Biko. Wits University Press. ISBN 978-1-86814-464-8. Wa Thingo, Ngugi (2009). Something Torn and New: An African Renaissance. Basic Civitas Books. ISBN 978-0-465-00946-6. Wiwa, Ken (2001). In the Shadow of a Saint: A Son's Journey to Understand His Father's Legacy. Steerforth. ISBN 978-1-58642-025-3. Woods, Donald (2004). Rainbow Nation Revisited: South Africa's Decade of Democracy. Andre Deutsch. ISBN 978-0-233-00052-7.
== History == The idea that the stomach produces a hormone to trigger acid secretion was first put forward by British physiologist John Sydney Edkins in 1905. Working with cats, he found that injecting extracts from the stomach lining causes an increase in acid production, and he called the substance responsible "gastrin". His theory was met with skepticism after histamine was discovered in 1910, as it had a similar effect on the stomach, leading many scientists to doubt whether gastrin was a separate hormone at all. The debate was largely settled in 1942, when Simon Komarov published research showing that a gastrin extract could stimulate acid secretion on its own, separate from histamine. Building on this work, Roderic Gregory and Hilda Tracy isolated the hormone in purified form in the early 1960s and identified two closely related versions, which they named gastrin I and gastrin II. Chemist George Kenner then determined the full amino acid sequence of both peptides, making gastrin the first gut hormone to have its complete structure worked out.
=== Segmental and molecular motions === In addition to providing static information on molecules by determining their 3D structures, one of the remarkable advantages of NMR over X-ray crystallography is that it can be used to obtain important dynamic information. This is due to the orientation dependence of the chemical-shift, dipole-coupling, or electric-quadrupole-coupling contributions to the instantaneous NMR frequency in an anisotropic molecular environment. When the molecule or segment containing the NMR-observed nucleus changes its orientation relative to the external field, the NMR frequency changes, which can result in changes in one- or two-dimensional spectra or in the relaxation times, depending on the correlation time and amplitude of the motion.
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.